Differential effects of zidovudine and zidovudine triphosphate on mitochondrial permeability transition and oxidative phosphorylation

British Journal of Pharmacology

Volumn 121, Issue 7, 1997, Pages 1295-1300

  Elimadi, Aziz ^a,d   Morin, Didier ^a,b   Albengres, Edith ^a   Chauvet Monges, Anne Marie ^c   Allain, Valérie ^c   Crevat, Aimé ^c   Tillement, Jean Paul ^a  

^a Clinical Pharmacology Unit   (France)

^b CNRS   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

^d FACULTÉ DE MÉDECINE   (France)

Author keywords

Adenine nucleotide carrier (ANC); ADP; ATP; Atractyloside; Liver mitochondria; Mitochondrial permeability transition (MPT); Swelling; Zidovudine (ZDV); Zidovudine 3P (ZDV 3P)

Indexed keywords

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; ATRACTYLOSIDE; CALCIUM ION; TRITIUM; ZIDOVUDINE; ZIDOVUDINE 5' TRIPHOSPHATE;

ANIMAL TISSUE; ARTICLE; BINDING SITE; CONTROLLED STUDY; MALE; MEMBRANE PERMEABILITY; MITOCHONDRIAL MEMBRANE; MITOCHONDRIAL RESPIRATION; NONHUMAN; NUCLEOTIDE METABOLISM; OXIDATIVE PHOSPHORYLATION; PRIORITY JOURNAL; RADIOASSAY; RAT;

ADENOSINE TRIPHOSPHATE; ANIMALS; ANTIVIRAL AGENTS; CALCIUM; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MITOCHONDRIA, LIVER; MITOCHONDRIAL SWELLING; OXIDATIVE PHOSPHORYLATION; RATS; RATS, WISTAR; THYMINE NUCLEOTIDES; ZIDOVUDINE;

EID: 0030739644     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0701276     Document Type: Article

References (30)

1. 2+ binding sites with opposing effects on the pore open probability. J. Biol. Chem., 268, 1005 1010.
2. CARBONERA, D. & AZZONE, G.F. (1988). Permeability of inner mitochondrial membrane and oxidative stress. Biochem. Biophys. Acta, 943, 245 255.
3. CHEN, C.A., BARKER, S.M., MITCHEL, D.H., STEVENS, S.M., O'NEILL, P. & CUNNINGHAM, A.L. (1992). Concurrent zidovudine-induced myopathy and hepatotoxicity in patients treated for human immunodeficiency virus (HIV) infection. Pathology, 24, 109-111.
4. DALAKAS, M.C., PEZESHKPOUR, G.H., LANKAITIS, J.P., COHEN, B. & GRIFFIN, J.L. (1990). Mitochondrial myopathy caused by long-term zidovudine therapy. N. Engl. J. Med., 322, 1098 1105.
5. DALAKAS, M.C. & PEZESHKPOUR, G.H. (1988). Neuromuscular diseases associated with human immunodeficiency virus infection. Ann. Neurol., 23 (suppl.), S38-S48.
6. DE MACEDO, D.V., NEMOPUCENO, M.F. & PEREIRA-DI-SILVA, L. (1993). Involvement of the ADP/ATP carrier in permeabilization processes of the inner mitochondrial membrane. Eur. J. Biochem., 215, 595-600.
7. FISCHL, M.A., RICHMAN, D.D., GRIECO, M.H., VOLBERDING, C.A., LASKIN, O.L., LEEDOM, J.M., CROOPMAN, J.E., MILDRAN, D. & SCHOOLEY, R.T. (1987). The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS related complex. A double-blind placebo control trial. N. Engl. J. Med., 317, 185 191.
8. FURMAN, P.A., EYFE, J.A., ST. CLAIR, M.H., WEINHOLD, K., RIDEOUT, J.L., FREEMAN, G.A., LEHRMAN, S.N., BOLOGNESI, D.P., BRODER, S., MITSUYA, H. & BARRY, D.W. (1986). Phosphorylation of 3′-azido-3′deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase. Proc. Natl. Acad. Sci. U.S.A., 83, 8333-8337.
9. GUNTER, T.E. & PFEIFFER, D.R. (1990). Mechanisms by which mitochondria transport calcium. Am. J. Physiol., 258, C755-C786.
10. 2+-induced large amplitude swelling of liver heart mitochondria by cyclosporine A is probably caused by the inhibition binding to mitochondrial matrix peptidyl-prolyl-cis-trans-isomerase and preventing its interacting with the adenine nucleotide translocase. Biohem. J., 268, 153 160.
11. 2+ trigger site. Arch. Biochem. Biophys., 195, 460-467.
12. HELBERT, M., FLETCHER, T., PEDDLE, B., HARRIS, J.R.W. & PINCHING, A.J. (1988). Zidovudine-associated myopathy. Lancet, ii, 689-690.
13. JOHNSON, D. & LARDY, H.A. (1967). Isolation of liver and kidney mitochondria. In Methods in Enzymology. ed. Estabook, R.W. & Pullman, M., Vol. 10, pp. 94-96, New-York: Academic Press.
14. KORZENIEWSKI, B. & MAZAT, J. (1996). Theoretical studies on the control of oxidative phosphorylation in muscle mitochondria: application to mitochondrial deficiencies. Biochem. J., 319, 143 148.
15. LAMPERTH, L., DALAKAS, M.C., DAONI, F., ANDERSON, J. & FERRARI, R. (1991). Abnormal skeletal and cardiac muscle mitochondria induced by zidovudine (AZT) in human muscle in vitro and in an animal model. Lab. Invest., 65, 742 751.
16. LAPIDUS, R.G. & SOKOLOVE, P.M. (1992). Inhibition by spermine of the inner membrane permeability transition of isolated rat heart mitochondria. FEBS Lett., 313, 314-318.
17. LE QUOC, K. & LE QUOC, D. (1988). Involvement of the ADP ATP carrier in calcium-induced perturbations of the mitochondrial inner membrane permeability: importance of the orientation of the nucleotide binding site. Arch. Biochem. Biophys., 265, 249 257.
18. LEWIS, W., GONZALEZ, B., CHOMYN, A. & PAPOIAN, T. (1992). Zidovudine induces molecular, biochemical and ultrastructural changes in rat skeletal muscle mitochondria. J. Clin. Invest., 89, 1354-1360.
19. LOWRY, O.H., ROSEBROUGH, N.J., FARR, A.I., RANDALL, R.J. (1951). Protein measurement with the folin phenol reagent. J. Biol. Chem., 193, 265-275.
20. MARTY, I., BRANDOLIN, G., GAGNON, J., BRASSEUR, R. & VIGNAIS, P.V. (1992). Topography of the membrane bound ADP/ATP carrier assessed by enzymatic proteolysis. Biochemistry, 31, 4058-4065.
21. MHIRI, C., BAUDRIMENT, M., BONNE, G., GENY, C., DEGOUL, F., MARSAC, C., ROULLET, E. & GHERARDI, R. (1991). Zidovudine myopathy: a distinctive disorder associated with mitochondrial dysfunction. Ann. Neurol., 29, 601-614.
22. NAPOLITANO, J.S.M. (1993). AZT causes tissue-specific inhibition of mitochondrial bioenergetic function. Biochem. Biophys. Res. Commun., 194, 170-177.
23. SALES, S.D., VEAL, G.J., HART, C.A. & BACK, D.J. (1996). Zidovudine (ZDV) cytotoxicity in vitro linked to intracellular ZDV-monophosphate concentrations. Br. J. Clin. Pharmacol., 42, 671P-672P.
24. 31P in vivo magnetic resonance spectroscopy. J. Clin. Invest., 96, 126 131.
25. SOMMADOSSI, J.P., CARLISLE, R. & ZHOU, Z. (1989). Cellular pharmacology of 3′-azido-3′-deoxythymidine with evidence of incorporation into DNA of human bone marrow cells. Mol. Pharmacol., 36, 9 14.
26. SZABO, I., BERNARDI, P. & ZORATTI, M. (1992). Modulation of the mitochondrial megachannel by divalents cations and protons. J. Biol. Chem., 267, 2940 2946.
27. 2+ and phosphate. Biochem. Biophys. Res. Commun., 111, 792-797.
28. URIEN, S. (1995). Micropharm-K, a microcomputer interactive program for the analysis and simulation of pharmacokinetics processes. Pharm. Res., 12, 1225 1230.
29. VILSON, D.F. (1994). Factors affecting the rate and energetics of mitochondrial oxidative phosphorylation. Med. Sci. in Sports and Exercise, 26, 37-43.
30. WEILAND, G.A. & MOLINOFF, P.B. (1981). Minireview: quantitative analysis of drug-receptor interactions: I. Determination of kinetic and equilibrium properties. Life Sci. 29, 313-330.